Literature DB >> 15965645

Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes.

X H Wang1, Y Qin, M H Hu, Y Xie.   

Abstract

Dendritic cells (DCs) are one of the most potent antigen-presenting cells (APCs) capable of activating immune responses. Different forms of tumor antigens have been used to load DCs to initiate tumor-specific immune responses. Heat shock proteins (HSPs) are considered natural adjuvants which have the ability to chaperone peptides associated with them presented efficiently by interaction with professional APCs through specific receptors. In the present study, we used HSP, gp96-peptide complexes, derived from human hepatocellular carcinoma (HCC) cells as antigens for pulsing DCs. We found that gp96-peptide complexes derived from HCC cells induced the maturation of DCs by enhancing expression of human leukocyte antigen class II, CD80, CD86, CD40, and CD83. The matured DCs stimulated a high level of autologous T cell proliferation and induced HCC specific cytotoxic T lymphocytes, which specifically killed HCC cells by a major histocompatability complex (MHC) class I restricted mechanism. These findings demonstrate that DCs pulsed with gp96-peptide complexes derived from HCC cells are effective in activating specific T cell responses against HCC cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15965645     DOI: 10.1007/s00262-005-0662-9

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  8 in total

1.  A novel tuberculosis antigen identified from human tuberculosis granulomas.

Authors:  Yang Yu; Dongdong Jin; Shizong Hu; Yan Zhang; Xiaojing Zheng; Jianhua Zheng; Mingfeng Liao; Xinchun Chen; Michael Graner; Haiying Liu; Qi Jin
Journal:  Mol Cell Proteomics       Date:  2015-01-20       Impact factor: 5.911

Review 2.  Personalized dendritic cell-based tumor immunotherapy.

Authors:  Nona Janikashvili; Nicolas Larmonier; Emmanuel Katsanis
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

3.  Identification and Validation of Genomic Subtypes and a Prognostic Model Based on Antigen-Presenting Cells and Tumor Microenvironment Infiltration Characteristics in Hepatocellular Carcinoma.

Authors:  Ji Chen; Chunxue Li; Zhichao Lang; Jianjian Zheng; Suhui Yu; Zhenxu Zhou
Journal:  Front Oncol       Date:  2022-06-03       Impact factor: 5.738

4.  Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells loaded with hepatocellular carcinoma -derived RNA or cell lysate.

Authors:  Ke Pan; Jing-jing Zhao; Hui Wang; Jian-jun Li; Xiao-ting Liang; Jian-cong Sun; Yi-bing Chen; Hai-qing Ma; Qing Liu; Jian-chuan Xia
Journal:  Int J Biol Sci       Date:  2010-10-13       Impact factor: 6.580

5.  Polyamine compound deoxyspergualin inhibits heat shock protein-induced activation of immature dendritic cells.

Authors:  Atsushi Sugawara; Toshihiko Torigoe; Yasuaki Tamura; Kenjiro Kamiguchi; Kyuichi Nemoto; Hiroshi Oguro; Noriyuki Sato
Journal:  Cell Stress Chaperones       Date:  2008-08-07       Impact factor: 3.667

6.  Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.

Authors:  Liang Shi; Hui Lin; Gonghui Li; Ren-An Jin; Junjie Xu; Yin Sun; Wen-Lung Ma; Shuyuan Yeh; Xiujun Cai; Chawnshang Chang
Journal:  Mol Cancer Ther       Date:  2016-03-03       Impact factor: 6.261

7.  Regulation of the expression of chaperone gp96 in macrophages and dendritic cells.

Authors:  Lutz Wolfram; Anne Fischbeck; Isabelle Frey-Wagner; Kacper A Wojtal; Silvia Lang; Michael Fried; Stephan R Vavricka; Martin Hausmann; Gerhard Rogler
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

8.  An engineered non-toxic superantigen increases cross presentation of hepatitis B virus nucleocapsids by human dendritic cells.

Authors:  Julie D McIntosh; Kristy Manning; Shilpa Chokshi; Nikolai V Naoumov; John D Fraser; P Rod Dunbar; John A Taylor
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.